


USPTO Form 1362 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 9000/2023		Serial No. 10/676,424		
				Applicant(s): Falt, et al.				
				Filing Date: October 1, 2003		Group: 1638		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	1.	6,500,617 B1	Dec. 31, 2002	Stemmer, et al.	435	6	Apr. 22, 1999	
	2.	5,716,831	Feb. 10, 1998	Whalon, et al.	435	19	May 24, 1995	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
MM	3.	Ciesla, et al.; "Mapping Effectiveness of Insecticide Treatments against Pandora Moth with Color-IR Photos"; (1984); Vol. 50, No. 1, pp. 73-79.						
MM	4.	Copy of International Search Report dated July 23, 2004. P. 1						
EXAMINER <i>M. Miller</i>					DATE CONSIDERED <i>4/5/06</i>			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>								
<small>**Copies of references not provided at the time of this submission.</small>								



U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 9000/2023		Serial No. 10/676,424	
INFORMATION DISCLOSURE STATEMENT							
Applicant(s): Falt, et. al.						Group: 1638 1631	
Filing Date: October 1, 2003							
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation
							YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
MM	1.	Brand, A.H. et al., "Targeted gene expression as means of altering cell fates and generating dominant phenotypes", <i>Development</i> , 118:401-415 (1993).					
↑	2.	Chan, H. et al., "Drosophila models of human neurogenerative disease", <i>Cell Death Differ.</i> , 7:1075-1080 (2000).					
	3.	Feany, M.B. et al., "A Drosophila model of parkinson's disease", <i>Nature</i> , 404:394-398 (2000).					
	4.	Fernandez-Funez, P. et al., "Identification of genes that modify ataxin-1-induced neurodegeneration", <i>Nature</i> , 408:101-106 (2000).					
	5.	Fortini, M.E. et al., "Modeling human neurodegenerative diseases in Drosophila", <i>Trends Genet.</i> 16(4):161-167 (2000)					
	6.	Jackson, G.R. et al., "Polyglutamine-Expanded Human Huntingtin Transgenes Induce Degeneration of Drosophila Photoreceptor Neurons", <i>Neuron</i> , 21:633-642 (1998).					
	7.	Kazemi-Esfarjani, P. et al., "Genetic Suppression of Polyglutamine Toxicity in Drosophila", <i>Science</i> , 287:1837-1840 (2000).					
	8.	Marsh, J.L. et al, "Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila", <i>Hum. Mol. Genet.</i> 9(1):13-25 (2000).					
U	9.	Warrick, J.M. et al., "Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in Drosophila", <i>Cell</i> 93:939-949 (1998).					
EXAMINER M. Miller					DATE CONSIDERED 4/5/06		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							